Babic Aleksandar M
Department of Pathology, Brigham and Women's Hospital and Joint Program in Transfusion Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Am J Hematol. 2008 Jul;83(7):589-91. doi: 10.1002/ajh.21166.
Photopheresis, initially established as an effective treatment of cutaneous T-cell lymphoma, has in recent years also been used to treat chronic graft vs. host disease, heart transplant rejection, and several other conditions requiring immunosuppression. Despite reported beneficial results of this procedure in treatment of various conditions, randomized controlled clinical trials are lacking for the majority of suggested indications. Furthermore, the mechanisms of action of this procedure are still unclear. Deeper understanding of the molecular basis of photopheresis-based immunomodulation will allow better selection of patients to be treated and will facilitate development of novel, minimally toxic immunomodulatory treatments.
光分离置换疗法最初作为治疗皮肤T细胞淋巴瘤的一种有效方法被确立，近年来也被用于治疗慢性移植物抗宿主病、心脏移植排斥反应以及其他一些需要免疫抑制的病症。尽管该疗法在治疗各种病症方面已有有益效果的报道，但对于大多数建议的适应症而言，仍缺乏随机对照临床试验。此外，该疗法的作用机制仍不明确。更深入地了解光分离置换疗法免疫调节的分子基础，将有助于更好地选择接受治疗的患者，并促进新型、低毒免疫调节疗法的开发。
